0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Brief Communications |

Interferon-α Treatment of Four Patients with the Churg-Strauss Syndrome

Efstratios Tatsis, MD; Armin Schnabel, MD; and Wolfgang L. Gross, MD
[+] Article and Author Information

From the Medical University of Lubeck, Lubeck, Germany; and Rheumaklinik Bad Bramstedt, Bad Bramstedt, Germany. For current author addresses, see end of text. Requests for Reprints: Efstratios Tatsis, MD, Poliklinik fur Rheumatologie, Medizinische Universitat zu Lubeck, Ratzeburger Allee 160, 23538 Lubeck, Germany. Current Author Addresses: Drs. Tatsis, Schnabel, and Gross: Department of Rheumatology, Medical University of Lubeck, 23538 Lubeck, and Rheumaklinik Bad Bramstedt, 24572 Bad Bramstedt, Germany.


Copyright ©2004 by the American College of Physicians


Ann Intern Med. 1998;129(5):370-374. doi:10.7326/0003-4819-129-5-199809010-00004
Text Size: A A A

Background: Interferon-α is reported to have a beneficial effect on patients with the idiopathic hypereosinophilic syndrome.

Objective: To study the effect of interferon-α on the Churg-Strauss syndrome.

Design: Case series.

Setting: University hospital.

Patients: Four patients with biopsy-proven Churg-Strauss syndrome.

Intervention: Interferon-α at dosages of 7.5 to 63 million U per week.

Measurements: Disease extent, disease activity, and blood eosinophil count in a treatment period ranging from 14 to 25 months.

Results: Interferon-α therapy led to remission of disease and a substantial reduction of the prednisolone requirement in two patients who had attained incomplete remission with cyclophosphamide or methotrexate. The third patient's condition stabilized, and the fourth patient maintained remission. During interferon-α therapy, the blood eosinophil count in all patients decreased in a dose-dependent manner and paralleled the extent of clinical disease and disease activity.

Conclusions: Interferon-α may be an effective treatment for the Churg-Strauss syndrome. It seems to exert its effect primarily by producing a dose-dependent decrease in the blood eosinophil count.

Figures

Grahic Jump Location
Figure 1.
Blood eosinophil counts (triangles), disease extent index scores (circles), and dosages of interferon-α and prednisolone in four patients with the Churg-Strauss syndrome. Top.Upper middle.Lower middle.Bottom.[9]

Patient 1. Patient 2. Patient 3. Patient 4. Time 0 represents the beginning of interferon-α therapy for each patient. The disease extent index is a measure of the number of organ systems involved (range, 0 to 21 points ). IFN-α = interferon-α; MU = million units; PRED = prednisolone.

Grahic Jump Location

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Churg Strauss Interferon Treatment
Posted on April 9, 2004
Larry Geyerman
University of Arizona
Conflict of Interest: None Declared

I am a Churg Stauss Syndrome patient and wondered if there was any follow up 5 years on after the article research on "Interferon-alpha Treatment of Four Patients with the Churg-Strauss Syndrome " by E. Tasis

Conflict of Interest:

None declared

Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)